Parkinson’s disease (PD) is a common progressive neurodegenerative disorder with multifactorial etiology. While dopaminergic medication is the standard therapy in PD, it provides limited symptomati...
Background: Identifying causes of falls for people with Parkinson’s disease has met with limited success. Prospective falls measurement using the “gold standard” approach is challenging. This paper examines the process and outcomes associated with longitudinal falls reporting in this population. Methods: Participants were recruited from ICICLE-GAIT (a collaborative study with ICICLE-PD; an incident cohort study). Monthly falls diaries were examined over 48 months for accuracy of data and rate of attrition. To further inform analysis, characteristics of participants with 36-month completed diaries were compared with those who did not complete diaries. Results: One hundred and twenty-one participants were included at baseline. By 12 months, falls diary data had reduced to 107 participants; to 81 participants by 36 months; and to 59 participants by 48 months. Key reasons for diary attrition were withdrawal from ICICLE-gait (n = 16) (13.2%), and noncompliance (n = 11) (9.1%). The only significant difference between the completed and non-completed diary groups was age at 36 months, with older participants being more likely to send in diaries. Conclusions: Prospective falls data is feasible to collect over the long term. Attrition rates are high; however, participants retained in the study are overall representative of the total falls diary cohort.
Background: Gait impairment limiting mobility and restricting activities is common after stroke. Auditory rhythmical cueing (ARC) uses a metronome beat delivered during exercise to train stepping and early work reports gait improvements. This study aimed to establish the feasibility of a full scale multicentre randomised controlled trial to evaluate an ARC gait and balance training programme for use by stroke survivors in the home and outdoors. Methods: A parallel-group observer-blind pilot randomised controlled trial was conducted. Adults within 2 years of stroke with a gait-related mobility impairment were recruited from four NHS stroke services and randomised to an ARC gait and balance training programme (intervention) or the training programme without ARC (control). Both programmes consisted of 3x30 min sessions per week for 6 weeks undertaken at home/nearby outdoor community. One session per week was supervised and the remainder self-managed. Gait and balance performance assessments were undertaken at baseline, 6 and 10 weeks. Key trial outcomes included recruitment and retention rates, programme adherence, assessment data completeness and safety. Results: Between November 2018 and February 2020, 59 participants were randomised (intervention n=30, control n=29), mean recruitment rate 4/month. At baseline, 6 weeks and 10 weeks, research assessments were conducted for 59/59 (100%), 47/59 (80%) and 42/59 (71%) participants, respectively. Missing assessments were largely due to discontinuation of data collection from mid-March 2020 because of the UK COVID-19 pandemic lockdown. The proportion of participants with complete data for each individual performance assessment ranged from 100% at baseline to 68% at 10 weeks. In the intervention group, 433/540 (80%) total programme exercise sessions were undertaken, in the control group, 390/522 (75%). Falls were reported by five participants in the intervention group, six in the control group. Three serious adverse events occurred, all unrelated to the study. Conclusion: We believe that a definitive multicentre RCT to evaluate the ARC gait and balance training programme is feasible. Recruitment, programme adherence and safety were all acceptable. Although we consider that the retention rate and assessment data completeness were not sufficient for a future trial, this was largely due to the UK COVID-19 pandemic lockdown. Trial registration: ISRCTN, ISRCTN10874601, Registered on 05/03/2018,
Background: Gait and cognitive impairments are hallmark features of Parkinson's disease (PD) that significantly impact quality of life. These deficits arise from both dopaminergic and non-dopaminergic mechanisms, including cholinergic dysfunction. Transcutaneous cervical vagus nerve stimulation (tcVNS) is a non-invasive neuromodulatory technique that may enhance cholinergic function and has potential therapeutic relevance for individuals with PD. However, its feasibility, acceptability, adherence, and safety in a domiciliary setting remain unclear. We conducted a single-centre, double-blind, parallel, sham-controlled, randomised proof-of-concept study. Objectives: The primary objective was to assess the feasibility, acceptability, adherence, and safety of home-based tcVNS. The secondary objective was to explore preliminary effects on gait and cognitive function. Methods: Thirty-three participants with PD were randomised to either active ( n = 16) or sham ( n = 17) tcVNS and self-administered two stimulations twice daily for 12 weeks, followed by a 24-week post-intervention follow-up. Results: Retention was high (93.9%), with two participants withdrawing from the sham group for reasons unrelated to the intervention. No serious adverse events were reported during the intervention period. Mild adverse events led to discontinuation of tcVNS use in three active and two sham participants. tcVNS had minimal effects on gait and cognition, although small, non-significant improvements in step length variability were observed. Conclusions: This study represents the longest tcVNS intervention trial in PD to date and supports the feasibility, acceptability, and safety of domiciliary tcVNS. While preliminary findings suggest tcVNS may have therapeutic potential, larger trials are needed to establish its effectiveness for improving gait and cognitive function in PD.